Reports
Sale
Peptic Ulcer Drugs Market Size, Share, Growth, Analysis: By Product Type: Proton Pump Inhibitor, H2 Antagonist, Antibiotics, Antacids, Ulcer Protective; By Disease Indication: Gastritis, Gastric Ulcer, Duodenal Ulcer, GERD, Others; By Distribution Channel: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Peptic Ulcer Drugs Market Outlook
The peptic ulcer drugs market size was valued at USD 6.12 billion in 2023, driven by the rising prevalence of peptic ulcers across the 8 major markets. The market is expected to grow at a CAGR of 3.80% during the forecast period of 2024-2032, with the values likely to rise from USD 6.35 billion in 2024 to USD 8.56 billion by 2032.
Peptic Ulcer Drugs Market Overview
Peptic ulcers are characterized by open sores on the lining of the esophagus, stomach, or small intestine. The most common symptom is pain in the upper abdominal region. It is usually caused by the bacterium Helicobacter pylori and long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin. Peptic ulcers affect 1 out of 12 individuals in the United States with 1 in 5 cases associated with the bacterial infection . The rising prevalence of the disease is one of the key factors driving the peptic ulcer drugs market demand and is anticipated to accelerate the growth of the market in the forecast period.
The surge in drug approvals by the health regulatory bodies is expected to further bolster the market growth. In October 2023, the United States Food and Drug Administration (FDA) approved reformulated vonoprazan tablets for Voquezna Triple Pak and Voquezna Dual Pak to treat Helicobacter pylori infection in adults. Developed by Phathom Pharmaceuticals, a United States-based biopharmaceutical company, these drugs combine antibiotics with vonoprazan, a novel potassium-competitive acid blocker. This new class of acid suppression therapy offers promising H. pylori eradication rates. The company plans to commercially launch it in December 2023 for H. pylori treatment.
The peptic ulcer drugs market share is also expected to experience a significant expansion due to increasing research and development activities backed by robust support from the government. Moreover, the growing geriatric population and advancement in the healthcare system will also boost the market growth.
Peptic Ulcer Drugs Market Segmentation
Market Breakup by Product Type
- Proton Pump Inhibitor
- H2 Antagonist
- Antibiotics
- Antacids
- Ulcer Protective
Based on the product type, the market covers various therapeutics used in the treatment and management of peptic ulcers. These include proton pump inhibitors, H2 antagonists, antibiotics, antacids, and ulcer protective.
Market Breakup by Disease Indication
- Gastritis
- Gastric Ulcer
- Duodenal Ulcer
- GERD
- Others
The peptic ulcer drugs market is divided by disease indication, which includes gastritis, gastric ulcer, duodenal ulcer, and GERD, among others. This segmentation represents the various conditions for which peptic ulcer drugs are prescribed.
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Peptic ulcer drugs are distributed to the users through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, among others. Each distribution channel offers unique advantages and conveniences for patients seeking access to peptic ulcer medications.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The report covers 8 major markets poised to witness significant peptic ulcer drugs market growth in upcoming years. It is divided into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market for peptic ulcer drugs which can be attributed to the rising cases of the disease, along with the growing healthcare expenditure in the region.
Peptic Ulcer Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Orion Corporation
- Bausch Health Companies Inc.
- CYTOKINETICS, INC.
- Aquestive Therapeutics, Inc.
- Sanofi
- Covis Pharma
- Sun Pharmaceuticals Industries Ltd
- Mitsubishi Tanabe Pharma Corporation
- BrainStorm Cell Limited
- ViroMed Co., Ltd
- Ionis Pharmaceuticals
- Genervon Biopharmaceuticals, LLC
- Biogen
- Orphazyme A/S
- F. Hoffmann-La Roche Ltd
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Disease Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Peptic Ulcer Drugs Market Report
- How is the market landscape expected to evolve in coming years?
- What are the major market trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What factors contribute to the rising peptic ulcers market demand?
- What is the incidence and epidemiology of peptic ulcers?
- What are the different types of peptic ulcer drugs available in the market?
- What are the latest advancements in peptic ulcer drug research and development, including novel drug candidates and formulations?
- Which drugs are under clinical trials?
- What were the major drug approvals used to manage peptic ulcers during the historical period?
- Which major drug manufacturers are expected to lead the market?
- What are the key strategies adopted by leading pharmaceutical companies to gain market share?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics of peptic ulcer drugs?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Peptic Ulcer Drugs Market Overview – 8 Major Markets
3.1 Peptic Ulcer Drugs Market Historical Value (2017-2023)
3.2 Peptic Ulcer Drugs Market Forecast Value (2024-2032)
4 Peptic Ulcer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Disease Indication Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Disease Indication Success Rate
6 Peptic Ulcer Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.5 India Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
7 Peptic Ulcer Drugs Market Landscape – 8 Major Markets
7.1 Peptic Ulcer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Peptic Ulcer: Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Disease Indication
7.2.3 Analysis by Distribution Channel
8 Peptic Ulcer Challenges and Unmet Needs
8.1 Disease Indication Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Disease Indication
10 Peptic Ulcer Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Peptic Ulcer Drugs Market Segmentation (2017-2032) - 8 Major Markets
11.1 Peptic Ulcer Drugs Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Proton Pump Inhibitor
11.1.3 H2 Antagonist
11.1.4 Antibiotics
11.1.5 Antacids
11.1.6 Ulcer Protective
11.2 Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
11.2.1 Market Overview
11.2.2 Gastritis
11.2.3 Gastric Ulcer
11.2.4 Duodenal Ulcer
11.2.5 GERD
11.2.6 Others
11.3 Peptic Ulcer Drugs Market (2017-2032) by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Peptic Ulcer Drugs Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Peptic Ulcer Drugs Market (2017-2032)
12.1 United States Peptic Ulcer Drugs Market Historical Value (2017-2023)
12.2 United States Peptic Ulcer Drugs Market Forecast Value (2024-2032)
12.3 United States Peptic Ulcer Drugs Market (2017-2032) by Product Type
12.3.1 Market Overview
12.3.2 Proton Pump Inhibitor
12.3.3 H2 Antagonist
12.3.4 Antibiotics
12.3.5 Antacids
12.3.6 Ulcer Protective
12.4 United States Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
12.4.1 Market Overview
12.4.2 Gastritis
12.4.3 Gastric Ulcer
12.4.4 Duodenal Ulcer
12.4.5 GERD
12.4.6 Others
13 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032)
13.1 EU-4 and United Kingdom Peptic Ulcer Drugs Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Peptic Ulcer Drugs Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Peptic Ulcer Drugs Market Overview
13.4 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032) by Product Type
13.4.1 Market Overview
13.4.2 Proton Pump Inhibitor
13.4.3 H2 Antagonist
13.4.4 Antibiotics
13.4.5 Antacids
13.4.6 Ulcer Protective
13.5 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
13.5.1 Market Overview
13.5.2 Gastritis
13.5.3 Gastric Ulcer
13.5.4 Duodenal Ulcer
13.5.5 GERD
13.5.6 Others
14 Japan Peptic Ulcer Drugs Market
14.1 Japan Peptic Ulcer Drugs Market Historical Value (2017-2023)
14.2 Japan Peptic Ulcer Drugs Market Forecast Value (2024-2032)
14.3 Japan Peptic Ulcer Drugs Market (2017-2032) by Product Type
14.3.1 Market Overview
14.3.2 Proton Pump Inhibitor
14.3.3 H2 Antagonist
14.3.4 Antibiotics
14.3.5 Antacids
14.3.6 Ulcer Protective
14.4 Japan Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
14.4.1 Market Overview
14.4.2 Gastritis
14.4.3 Gastric Ulcer
14.4.4 Duodenal Ulcer
14.4.5 GERD
14.4.6 Others
15 India Peptic Ulcer Drugs Market
15.1 India Peptic Ulcer Drugs Market (2017-2032) Historical Value (2017-2023)
15.2 India Peptic Ulcer Drugs Market (2017-2032) Forecast Value (2024-2032)
15.3 India Peptic Ulcer Drugs Market (2017-2032) by Product Type
15.3.1 Market Overview
15.3.2 Proton Pump Inhibitor
15.3.3 H2 Antagonist
15.3.4 Antibiotics
15.3.5 Antacids
15.3.6 Ulcer Protective
15.4 India Peptic Ulcer Drugs Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Gastritis
15.4.3 Gastric Ulcer
15.4.4 Duodenal Ulcer
15.4.5 GERD
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Product Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Product Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Product Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Orion Corporation
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bausch Health Companies Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 CYTOKINETICS, INC.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Aquestive Therapeutics, Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Sanofi
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Covis Pharma
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Sun Pharmaceuticals Industries Ltd
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Mitsubishi Tanabe Pharma Corporation
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 BrainStorm Cell Limited
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 ViroMed Co., Ltd
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Ionis Pharmaceuticals
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Genervon Biopharmaceuticals, LLC
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Biogen
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Orphazyme A/S
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 F. Hoffmann-La Roche Ltd
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
List not exhaustive!
23 Peptic Ulcer Disease Indication Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 6.12 billion in 2023 driven by the rising prevalence of peptic ulcers across 8 major markets.
The market is anticipated to grow at a CAGR of 3.8% during the forecast period of 2024-2032, likely to reach a market value of USD 8.56 billion by 2032.
The rising geriatric population susceptible to peptic ulcers as well as the increased healthcare expenditure are fuelling the demand for peptic ulcer drugs.
One of the significant trends in the market is the surge in drug approval by health regulatory agencies such as the FDA for the treatment of peptic ulcers.
Based on the product type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics, antacids, and ulcer protective.
Based on the disease indication, the market is segmented into gastritis, gastric ulcer, duodenal ulcer, and GERD, among others.
Major distribution channels of peptic ulcer drugs include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, and F. Hoffmann-La Roche Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER